MD Anderson and WHO establish international collaboration to reduce women’s cancers

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Obituary

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

Maura L. Gillison, MD, PhD, a medical oncologist and molecular epidemiologist whose work changed the standard of care for head and neck cancer by distinguishing human papillomavirus-positive from HPV-negative disease and thereby guiding diagnosis, treatment and prevention, died on June 21.

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Drugs & Targets

FDA approves Trodelvy for first-line treatment of mTNBC

FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.

July 02, 2026

Vol.52 No.26

In Brief

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Project Purple has awarded a $375,000 Research Recovery Grant to researchers at the University of Texas MD Anderson Cancer Center to continue critical pancreatic cancer research.

June 26, 2026

Vol.52 No.25

MD Anderson and WHO establish international collaboration to reduce women’s cancers

YOU MAY BE INTERESTED IN

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

FDA approves Trodelvy for first-line treatment of mTNBC

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Renew today!

Subscriber content

Never miss an issue!

Login